CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...

Two years ago, the UK became the first country to approve Casgevy, a Crispr-based therapy for the blood disorders sickle cell disease and β-thalassaemia. This year saw the world’s first personalised ...

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor growth. The technique worked even when only a fraction of tumor cells were ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common illnesses. So far, only 15 people have received the treatment. But, if all ...